Topics | RaQualia Pharma Inc.

Home
Topics

2012
2011
2010
2009
2008

2012

2012.02.08

Start of Phase II Study of the 2nd Generation (Atypical) Antipsychotic Drug Ziprasidone in Japan
2012.01.31

Composition of Matter Patent for Acid Pump Antagonist Approved in Korea

2011

2011.12.28

Pharmaceutical Executive Magazine Features RaQualia: December Issue Cover Story Highlights the Company’s Venture Model
2011.12.15

RaQualia Announces Clinical Research Collaboration with Chiba University Hospital
2011.12.02

RaQualia Announced That RaQualia President Was Selected as One of the Three Finalists in the Accelerating Category for 2011 EOY Japan
2011.11.14

Start of Phase I Study for Acid Pump Antagonist in Korea
2011.11.01

RaQualia’s CEO Featured in "Pharmaceutical Executive Magazine": Selected as One of 30 Leaders Globally Who Have Made a Difference
2011.10.14

RaQualia President will present at the BioCentury "NewsMakers" in the Biotech Industry Conference
2011.10.12

Ernst & Young Japan has selected RaQualia President as a semifinalist for 2011 Entrepreneur of the Year (EOY) Japan Award
2011.09.13

"BioCentury" featured Dr. Nagahisa's view on Open Innovation
2011.06.24

Dr. Nagahisa will lead a Special Session for "10th International Bio Forum & Bio Expo Japan"
2011.06.16

RaQualia Added a Novel COX-2 Inhibitor to its Portfolio
2011.04.07

RaQualia Announces an Executive Appointment

2010

2009

2009.12.14

RQ-00203078 (TRPM8) is highlighted in Thomson Pharma’s Overnight Report
2009.12.07

Non-confidential material for EP₄ Chronic Inflammatory Pain is now available
2009.11.05

Non-confidential materials for RaQualia's products are now available
2009.10.23

RaQualia made a poster presentation on TRPM8 Antagonist at Neuroscience 2009
2009.07.06

RQ-4 and RQ-10 are highlighted in Thomson Pharma's Overnight Reports
2009.04.30

RaQualia to exhibit at Digestive Disease Week

2008

2008.10.31

RaQualia web site opens.

Corporate Information: CEO Message; Company Overview; Vision, Management Principle and Culture; Corporate Governance; Business Model; Origins of Our Corporate Name and Logo; Facilities; Access; Press Release
Research & Development: Collaboration; Partnering in Research; What are Research Tools?; Research Tool Licensing

Product Information: Anidulafungin; Ziprasidone; Dalbavancin; EP₄ Antagonist; Cyclooxygenase-2 (COX-2) Inhibitor; Ghrelin Receptor Agonist; 5-HT₄ Partial Agonist; Acid Pump Antagonist; 5-HT_2B Antagonist; CB₂ Agonist; Motilin Receptor Agonist; Licensing

Shareholder and Investor Information

To our Shareholders and Investors

Vision, Management Principle and Culture

Corporate Governance

Outline of Securities Matters

IR Related News

Understanding RaQualia Pharma! RaQualia FAQ: RaQualia's History; What does RaQualia Pharma do?; How Does RaQualia Earn Revenues?; What About Dividends?; What are RaQualia's strengths?; What Does the Future Hold for RaQualia Pharma?

Corporate Introduction Video
Contributions to Society: Corporate Contributions; Contributions to the Community; Press Release; Topics